The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars

Acne Scars Clinical Trial

Official title:

The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02103816
• Other study ID #: CYN13-PRECIS-ACNE-BD
• Status: Completed
• Phase: N/A
• Start date: October 2013
• Est. completion date: February 2015

Study information

• Verified date: December 2020
• Source: Cynosure, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study to evaluate the SmartLipo Triplex laser system along with the SideLaze800 hand piece in the treatment of Acne Scars.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• A healthy male or female between 18 and 65 years old

• Has unwanted facial acne scars and wishes to undergo laser treatments.

• Is willing to consent to participate in the study.

• Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending follow up visits.

Exclusion Criteria:

• The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.

• The subject is hypersensitive to light exposure OR takes photo sensitized medication.

• The subject has active or localized systemic infections.

• The subject has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to the heavy use of aspirin) {greater than 81 mg per day}).

• The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within the planned treatment area 3 months prior to entering this study.

• The subject has used Accutane within 6 months prior to enrollment.

• The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.

• The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).

• The subject has a history of keloids.

• The subject has evidence of compromised wound healing.

• The subject has a history of squamous cell carcinoma or melanoma.

• The subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.

• The subject has an allergy to lidocaine and epinephrine.

• The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.

Related Conditions & MeSH terms

• Acne Scars
• Acne Vulgaris
• Cicatrix

Intervention

Device:
• SmartLipo Triplex laser system along with the SideLaze800 hand piece

Locations

Country	Name	City	State
United States	New Jersey Plastic Surgery	Montclair	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Cynosure, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Facial Acne Improvement Using the Global Aesthetic Improvement Scale	This assesses the level of improvement of acne scarring using the Global Aesthetic Improvement Scale. It is done through using photographic evaluation, comparing the baseline photograph to a photograph taken 3 months post the last treatment. The options for the acne scarring improvement are very much improved, much improved, improved, no change, or worse. The photographic evaluator decides this improvement based off of scar appearance differences amongst the photographs.	3 months post treatment
Secondary	Investigator Satisfaction Questionnaire	The investigator chooses if they are extremely satisfied, satisfied, slightly satisfied, slightly dissatisfied, dissatisfied, or extremely dissatisfied with the results.	3 months post treatment
Secondary	Subject Satisfaction Questionnaire	The subject chooses if they are extremely satisfied, satisfied, slightly satisfied, slightly dissatisfied, dissatisfied, or extremely dissatisfied with the results.	3 months post treatment